SCHEMBL4348993

SCHEMBL4348993

Cc1cccc(CNc2ccc(O)cc2O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
THRB P10828 1/20 0.46
ALOX12 P18054 1/20 0.46
KMT2A Q03164 1/20 0.46
DRD1 P21728 1/20 0.45
HTR2A P28223 1/20 0.45
ACHE P22303 1/20 0.44
BRD4 O60885 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
MAOB P27338 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
IDO1 P14902 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11512059 0.82 MEN1 (0.62) MAPTKDM4EMEN1ALDH1A1THRB
SCHEMBL6130238 0.79 IDO1 (0.56) MAPTKDM4EMEN1ALDH1A1THRB
SCHEMBL17243401 0.79 MRGPRX4 (0.46) MAPTKDM4EALDH1A1KMT2AACHE
SCHEMBL17243400 0.79 ALDH1A1 (0.44) MAPTKDM4EMEN1ALDH1A1THRB
SCHEMBL27761105 0.78 BRD4 (0.50) MAPTALDH1A1DRD1HTR2ABRD4
SCHEMBL4351082 0.78 RXFP1 (0.51) MEN1KMT2AMAOBIDO1CYP1A2
SCHEMBL4346359 0.77 BRD4 (0.49) DRD1HTR2ABRD4BRD9MAOB
SCHEMBL4342011 0.77 KDM4E (0.52) MAPTKDM4EMEN1ALDH1A1THRB
SCHEMBL4347717 0.76 MEN1 (0.69) MAPTKDM4EMEN1ALDH1A1THRB
SCHEMBL4346864 0.76 ALDH1A1 (0.55) MAPTKDM4EMEN1ALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885KDM4E 2662/4885MEN1 2168/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPT 4184/4885KDM4E 1689/4885MEN1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.